TLS Advisors’s Ovid Therapeutics OVID Stock Holding History

TLS Advisors’s Portfolio OVID Stock Details OVID Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$50.7K	Hold	18,858	–	–	0.15%	16
2026 Q1	$41K	Buy	18,858 +5,258	+39%	+$9.4K	0.1%	16
2025 Q4	$374K	Sell	13,600 -5,258	-28%	-$8.1K	0.98%	12
2025 Q3	$26K	Sell	18,858 -662,109	-97%	-$574K	0.08%	18
2025 Q2	$225K	Hold	680,967	–	–	0.7%	12
2025 Q1	$213K	Hold	680,967	–	–	0.48%	15
2024 Q4	$636K	Sell	680,967 -90,564	-12%	-$101K	1.45%	11
2024 Q3	$910K	Sell	771,531 -353,765	-31%	-$370K	1.92%	11
2024 Q2	$866K	Sell	1,125,296 -194,383	-15%	-$541K	2.17%	11
2024 Q1	$4.03M	Hold	1,319,679	–	–	9.37%	6
2023 Q4	$4.25M	Hold	1,319,679	–	–	14.1%	3
2023 Q3	$5.07M	Hold	1,319,679	–	–	20.5%	2
2023 Q2	$4.33M	Sell	1,319,679 -60,667	-4%	-$206K	18.57%	2
2023 Q1	$3.52M	Sell	1,380,346 -110,188	-7%	-$261K	18.08%	2
2022 Q4	$2.77M	Buy	+1,490,534	New	+$2.54M	13.66%	2

Other funds holding OVID

Jupiter Topco New York $245B AUM

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

AAA

Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

TLS Advisors's OVID Position: Q2 2026 in Review

TLS Advisors held its Ovid Therapeutics (OVID) position steady in Q2 2026 at 18,858 shares worth $50.7K. The position accounts for 0.15% of the portfolio, ranked #16.

TLS Advisors first reported a position in OVID in Q4 2022 and has held it in 15 quarters since. The position peaked at $5.07M in Q3 2023. 131 funds tracked by Wall St. Rank hold OVID as of Q2 2026.

TLS Advisors held 18,858 shares of Ovid Therapeutics worth $50.7K as of Q2 2026.
TLS Advisors left its Ovid Therapeutics share count unchanged in Q2 2026.
Ovid Therapeutics made up 0.15% of TLS Advisors's portfolio in Q2 2026, its #16 holding.
TLS Advisors first reported a position in Ovid Therapeutics in Q4 2022 and has held it in 15 quarters since.
TLS Advisors's Ovid Therapeutics position peaked at $5.07M in Q3 2023.
131 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2026.

Based on TLS Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.